Kevin R Ginnebaugh
Overview
Explore the profile of Kevin R Ginnebaugh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahmad A, Ginnebaugh K, Yin S, Bollig-Fischer A, Reddy K, Sarkar F
BMC Cancer
. 2015 Jul;
15:540.
PMID: 26206152
Background: For breast cancer patients diagnosed with estrogen receptor (ER)-positive tumors, treatment with tamoxifen is the gold standard. A significant number of patients, however, develop resistance to tamoxifen, and management...
2.
Ahmad A, Sayed A, Ginnebaugh K, Sharma V, Suri A, Saraph A, et al.
Am J Transl Res
. 2015 Apr;
7(2):298-308.
PMID: 25901198
We recently described the synthesis and characterization of a novel difluorinatedbenzylidene analog of curcumin, commonly referred as CDF, which demonstrated significantly enhanced bioavailability and in vivo anticancer activity. CDF targets...
3.
Ahmad A, Ginnebaugh K, Sethi S, Chen W, Ali R, Mittal S, et al.
Oncotarget
. 2015 Apr;
6(14):12188-95.
PMID: 25893380
Brain metastases are frequent in patients with advanced breast cancer and are associated with poor prognosis. However, unique molecular biomarkers have not yet been established. We hypothesized that microRNA-20b (miR-20b)...
4.
Ahmad A, Ginnebaugh K, Li Y, Padhye S, Sarkar F
Nutrients
. 2015 Jan;
7(1):321-34.
PMID: 25569626
The relevance of naturopathy (defined as the practice of medicine for the treatment of human diseases with natural agents) in human cancer is beginning to be appreciated, as documented by...
5.
Ginnebaugh K, Ahmad A, Sarkar F
Expert Opin Ther Targets
. 2014 Apr;
18(7):731-45.
PMID: 24758643
Introduction: The process of epithelial-to-mesenchymal transition (EMT) has long been advocated as a process during tumor progression and the acquisition of metastatic potential of human cancers. EMT has also been...
6.
Ahmad A, Maitah M, Ginnebaugh K, Li Y, Bao B, Gadgeel S, et al.
J Hematol Oncol
. 2013 Nov;
6(1):77.
PMID: 24199791
Background: Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) benefit Non-small cell lung cancer (NSCLC) patients, and an EGFR-TKIi erlotinib, is approved for patients with recurrent NSCLC. However, resistance to...